MSMariola Sasin-Rokita

Mariola Sasin-Rokita

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mariola Sasin-Rokita has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dried Blood Spot-Based Monitoring of Dietary Treatment in Children, Adolescents, and Young Adults with Inherited Disorders of Amino Acid Metabolism: A Four-Year Pilot Study

    by Agnieszka Kowalik, Ewa Głąb-Jabłońska, Joanna Taybert, Marta Nogalska, Mariola Sasin-Rokita, Magdalena Chełchowska, Joanna Myszkowska-Ryciak, Jolanta Sykut-Cegielska

    Background: Regular biochemical monitoring is essential for the safe and effective dietary treatment of inherited disorders of amino acid metabolism. However, conventional venous blood sampling may limit monitoring frequency and increase the burden on families. This study evaluated the feasibility and clinical usefulness of home-collected dried blood spot (DBS) samples analyzed using tandem mass spectrometry and additional chromatographic methods for dietary monitoring in inherited disorders of amino acid metabolism other than phenylketonuria. Methods: Between 2022 and 2025, children, adolescents, and young adults aged between 4 months and 20.5 years who were followed at a national metabolic center were monitored using DBS samples. The initial cohort included patients with maple syrup urine disease, tyrosinemia type III, homocystinuria, glutaric aciduria type 1, methylmalonic aciduria, isovaleric aciduria, argininosuccinic aciduria, methionine adenosyltransferase I/III deficiency, beta-ketothiolase deficiency, propionic aciduria, gyrate atrophy, and citrullinemia type 1. Disease-specific amino acids and metabolites were assessed to guide individualized dietary recommendations. Results: The number of monitored patients ranged from 24 to 40 per year. Overall annual completion rates of planned DBS measurements ranged from 56.7% to 73.0%, with additional clinically indicated samples collected in selected patients. DBS monitoring detected abnormal metabolite concentrations and supported dietary interventions, particularly in maple syrup urine disease, glutaric aciduria type 1, homocystinuria, tyrosinemia type III, and MAT I/III deficiency. In several other disorders, routine monthly DBS monitoring showed limited additional clinical value. Conclusions: DBS-based monitoring is a feasible approach that may support individualized dietary management in selected inherited disorders of amino acid metabolism, especially in early childhood and during periods of increased metabolic risk.

    • 4 December 2025
      • Vol. 29  (1) , 227-233
    Open Access

    Medium-chain Acyl-CoA Dehydrogenase Deficiency Identified by MS/MS Newborn Screening Challenges.

    by Ewa Głąb-Jabłońska, Joanna Taybert, Anna Wiśniewska, Mariola Sasin-Rokita, Mariusz Ołtarzewski, Magdalena Chełchowska

    Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency is an inborn error of metabolism resulting in the absence or reduced activity of the enzyme responsible for the β-oxidation of medium-chain fatty acids. MCAD deficiency can lead to metabolic decompensation, presenting as hypoketotic hypoglycaemia, hepatic encephalopathy (Reye-like syndrome), or death regardless of the patient's age. Blood samples in the national newborn screening programme were collected using 903 filter paper (dry blood spot - DBS). Routine dried blood spots from newborn screening (NBS) were analysed by flow injection and derivatised tandem mass spectrometry method (MS/MS). Positive screening cases in the MCAD deficiency profile were verified through GC/MS urine organic acid profiling and enzymatic and/or molecular testing. A total of 3,806,166 newborns were screened between 2014-2024, resulting in the identification of 94 cases of MCAD deficiency. Analysis of the obtained results revealed a consistent pattern in the levels of octanoylcarnitine (C8), hexanoylcarnitine (C6), and decanoylcarnitine (C10) acylcarnitines, as well as the C8/C10 ratio across these cases. Only one case of confirmed MCAD deficiency with an atypical acylcarnitine profile was found. The use of tandem mass spectrometry has enabled the inclusion of MCAD deficiency in newborn screening programmes. This has facilitated early detection, diagnosis, and initiation of therapeutic interventions to prevent metabolic decompensation. We emphasize the need for repeated sampling and further testing if C8 is even slightly elevated.